SARS-CoV-2 Spike receptor binding domain, RBD (348-357)- Lys(Biotin-LC) – 0.1 mg

Overview

The SARS-CoV-2 Spike receptor binding domain, RBD (348-357) – Lys(Biotin-LC) peptide is crucial for research into the coronavirus responsible for COVID-19. This specific peptide sequence encompasses residues 348 to 357 of the receptor binding domain, derived from the spike protein of SARS-CoV-2, with the sequence labeled using Biotin-LC at the C-terminus. This biotinylated peptide is designed for use in various assays, including detection and labeling applications, making it an essential component for studies focusing on viral entry mechanisms and therapeutic developments.

Key Features

• Peptide sequence: RBD (348-357) from SARS-CoV-2
• Biotin-LC labeling at the C-terminus for enhanced assay compatibility
• High purity and quality to ensure reliable experimental results
• Supports various applications, including immunoassays and protein interactions
• Perfect for researchers focused on COVID-19 and viral pathogens

Specifications

FAQ

What applications can this peptide be used for?

This peptide can be utilized in immunoassays, including ELISA and Western blotting, as well as study viral protein interactions and therapeutic targeting.

How should I store the SARS-CoV-2 Spike RBD peptide?

It is recommended to store the peptide at -20°C, avoiding repeated freeze-thaw cycles to maintain its integrity and functionality.

Is this peptide suitable for in vivo studies?

This peptide is primarily designed for in vitro applications. If you’re considering in vivo use, consult the relevant literature and your protocols to ensure appropriate applications.

This is an excellent opportunity to enhance your research with our high-quality peptides. Explore more from our extensive selection of peptides to meet your specific research needs.

Related Products

• PKG Substrate [RKRSRAE], Glasstide
• Autocamtide-2 [KKALRRQETVDAL]
• CREBtide [KRREILSRRPSYR], 5-FAM labeled